These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19376700)

  • 1. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2009 May; 19(10):2683-7. PubMed ID: 19376700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1617-22. PubMed ID: 18255290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
    Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
    ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
    Popescu L; Rau O; Böttcher J; Syha Y; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2007 Jul; 340(7):367-71. PubMed ID: 17610302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
    Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R
    Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.
    Le Naour M; Leclerc V; Farce A; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Lonchampt M; Dacquet C; Ktorza A; Berthelot P; Lebegue N
    ChemMedChem; 2012 Dec; 7(12):2179-93. PubMed ID: 23047286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
    Kim E; Park CS; Han T; Bae MH; Chong W; Lee CH; Shin YA; Ahn BN; Kim MK; Shin CY; Son MH; Kim JK; Moon HS; Shim HJ; Kim EJ; Kim SH; Lim JI; Lee CH
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4993-6. PubMed ID: 18771917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
    Makadia P; Shah SR; Pingali H; Zaware P; Patel D; Pola S; Thube B; Priyadarshini P; Suthar D; Shah M; Giri S; Trivedi C; Jain M; Patel P; Bahekar R
    Bioorg Med Chem; 2011 Jan; 19(2):771-82. PubMed ID: 21215640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
    Kuhn B; Hilpert H; Benz J; Binggeli A; Grether U; Humm R; Märki HP; Meyer M; Mohr P
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4016-20. PubMed ID: 16737814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
    Liutkus M; Caijo F; Girard AL; Ayral E; Audinot V; Boutin JA; Renard P; Caignard DH; Dacquet C; Ktorza A; Mosset P; Grée R
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):653-72. PubMed ID: 20518620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
    Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
    J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants.
    Kumar R; Ramachandran U; Srinivasan K; Ramarao P; Raichur S; Chakrabarti R
    Bioorg Med Chem; 2005 Jul; 13(13):4279-90. PubMed ID: 15869880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
    Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
    Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.